Reported 1 day ago
California is experiencing a pharmaceutical renaissance, with significant investments from companies like Amgen and Gilead driving innovations in science and logistics. Amgen's $600 million investment in a new science center aims to enhance R&D and therapeutic discovery, while Gilead's new Technical Development Hub focuses on accelerating biopharma innovation. These developments underscore the critical role of supply chain modernization in therapeutic delivery, emphasizing collaboration, transparency, and resilience in logistics, and positioning California as a central hub for the future of biopharmaceuticals.
Source: YAHOO